<DOC>
	<DOCNO>NCT02610192</DOCNO>
	<brief_summary>The purpose study evaluate clinical outcome follow single injection nSTRIDE Autologous Protein Solution female isolate patellofemoral osteoarthritis . A secondary objective study document duration treatment effect follow nSTRIDE injection .</brief_summary>
	<brief_title>nSTRIDE APS Females With Primary Patellofemoral Osteoarthritis</brief_title>
	<detailed_description>Clinical trial , general , formally demonstrate effectiveness safety various autologous therapy treatment knee OA . Differences process autologous therapy yield substantial difference result output . Thus , make generalization regard effectiveness across autologous therapy complicate . Each autologous therapy require independent efficacy evaluation . nSTRIDE APS show decrease pain , increase function favorable safety profile pilot trial . Further , demonstration treatment effect patellofemoral osteoarthritis , important subset knee osteoarthritis lack . This study evaluate population female patient patellofemoral osteoarthritis treatment modality provide limited/short live relief hope APS treatment provide extend relief patient . The study document treatment effect timeline treatment effect nSTRIDE APS follow single injection ( per symptomatic knee ) .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Patient must female Isolated patellofemoral osteoarthritis ( PFOA ) one knee diagnose treat physician Objective evidence PFOA one radiograph MRI take within 3 month treatment From 4065 year age , inclusive time injection Symptoms return need treatment within 3 month corticosteroid hyaluronic acid injection Willing able comply study procedure Sign inform consent form Any systematic inflammatory condition ( e.g . rheumatoid arthritis ) Active malignancy time injection Pregnant time injection Lactating time injection Knee joint infection skin disease infection area injection site Leukemia , metastatic malignant cell , receive chemotherapeutic treatment Participation another device , biologic drug study</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Autologous Protein Solution</keyword>
	<keyword>Patellofemoral Osteoarthritis</keyword>
	<keyword>Female</keyword>
</DOC>